Lilly Archives - Vista Partners LLC | HomeVista Partners LLC

From Couch to $50 Copay: Medicare’s Bridge Program and the Long‑Only Case for Obesity as a Chronic‑Care Asset Class -( $LLY MODD $NVO )

by John F. Heerdink, Jr. July 5, 2026 233Views 0Likes

Medicare’s new $50 GLP‑1 program and a fresh wave of insulin‑delivery innovation are quietly rewriting the economics of chronic care—and investors who blink risk missing a secular health‑tech rerating hiding inside the fine print. At the same time, companies like Modular Medical…

Biotech, Insulin Pumps, & Power Boards: Four Chronic‑Care Plays Quietly Rewriting the Healthcare Script -( $ABVX $LLY $MMED $MODD )

by John F. Heerdink, Jr. June 30, 2026 261Views 0Likes

Wall Street’s biotech and medtech set is quietly stitching together a new playbook for chronic disease – one that blends Phase 3 data, insulin hardware, boardroom star power, and China oncology. Ulcerative Colitis: Abivax Steps Onto Center Stage French biotech Abivax SA…

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

by John F. Heerdink, Jr. June 26, 2026 324Views 0Likes

Wall Street has a new favorite subplot in the diabetes and obesity saga: a three-act story where Sanofi (SNY) shores up the autoimmune front, Modular Medical (MODD) quietly rewires insulin delivery, and the GLP‑1 heavyweights audition next‑gen obesity drugs on the ADA…

Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI )

by John F. Heerdink, Jr. June 3, 2026 372Views 0Likes

The market is rewarding platforms that promise to rewrite instructions rather than merely manage symptoms. Eli Lilly and Company (LLY) is teaming up with privately held Ascidian Therapeutics in a deal valued at up to $1.9 billion, giving Lilly exclusive, target-specific rights…

Vaccine Valuations: Lilly’s 4 Billion Dollar Bet & GeoVax’s Focused Grind – ( $GOVX $LLY )

by John F. Heerdink, Jr. May 26, 2026 240Views 0Likes

Eli Lilly’s (LLY) latest vaccine shopping spree and GeoVax Labs’s (GOVX) sharpened strategic focus together seemingly sketch a quietly bullish subplot in an otherwise noisy biotech market, giving investors a fresh angle on infectious disease and immuno-oncology risk-on exposure. Big Pharma…

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

by John F. Heerdink, Jr. April 20, 2026 320Views 0Likes

Eli Lilly is turning its GLP-1 windfall into a broader oncology and radiopharma push, just as a new generation of targeted alpha therapies steps onto center stage with companies like NAYA Therapeutics — and investors are starting to notice that “weight loss”…

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

by John F. Heerdink, Jr. April 20, 2026 237Views 0Likes

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…

Tag: Lilly

From Couch to $50 Copay: Medicare’s Bridge Program and the Long‑Only Case for Obesity as a Chronic‑Care Asset Class -( $LLY MODD $NVO )

Biotech, Insulin Pumps, & Power Boards: Four Chronic‑Care Plays Quietly Rewriting the Healthcare Script -( $ABVX $LLY $MMED $MODD )

Inside the New Metabolic Gold Rush: How Sanofi’s Tzield, Modular Medical’s Pivot Pump and GLP‑1 Weight‑Loss Drugs Are Reshaping Diabetes Care -( $AZN $GPCR $LLY $MODD $NVO $PFE $SNY )

Lilly’s Ascidian Bet and NewLimit’s ‘Anti-Aging’ $3B Valuation Show Biotech’s Newest Obsession: Rewriting Biology Itself -( $COIN $LLY $XBI )

Vaccine Valuations: Lilly’s 4 Billion Dollar Bet & GeoVax’s Focused Grind – ( $GOVX $LLY )

From Waistlines to Warheads: How GLP‑1 Cash Is Quietly Fueling the Radiopharma Revolution -( $AZN $BMY $LLY )

From Shopping Carts to Smart Carts: Walmart’s Digital Health Push Meets Lilly’s GLP‑1 Boom – ( $AMGN $LLY $MODD $NVO $PFE $WMT )

Your Guide To Staying Informed In The Markets